In a liver fibrosis rat model stimulated by bile duct ligation, oral LF (300 mg/kg/day) treatment reduced inflammation and fibrosis of the liver via downregulation of the TGF-β1/Smad2 signalling pathway [48]. This evidence concerns the gene TGFB1 and Hepatic fibrosis.